Evidence map›Paper›PMID 41807576›Full record

ArticleScientific reports2026

The key m6A methylation regulator IGF2BP1 possesses potential prognostic value in papillary thyroid carcinoma.

Jinqiu Wang, Chen Dai, Mingze Wei, Weida Fu, Jin Luo, Yongping Dai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jinqiu WangDepartment of Thyroid and Breast Surgery, The First Affiliated Hospital of Ningbo University, Ningbo, 315000, Zhejiang, China.
Chen DaiDigestive Diseases Center, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, 518000, Guangdong, China.
Mingze WeiDepartment of Thyroid and Breast Surgery, The First Affiliated Hospital of Ningbo University, Ningbo, 315000, Zhejiang, China.
Weida FuDepartment of Thyroid and Breast Surgery, The First Affiliated Hospital of Ningbo University, Ningbo, 315000, Zhejiang, China.
Jin LuoDepartment of Thyroid and Breast Surgery, The First Affiliated Hospital of Ningbo University, Ningbo, 315000, Zhejiang, China.
Yongping DaiDepartment of Thyroid and Breast Surgery, The First Affiliated Hospital of Ningbo University, Ningbo, 315000, Zhejiang, China. daiyongp1969@163.com.

Funding

the "New Feather" Talent Program of the First Affiliated Hospital of Ningbo University XYJH-1-WJQthe Zhejiang Provincial Medical and Health Science and Technology Program 2022KY1110
6 · The paper itself

Abstract

Papillary thyroid carcinoma (PTC) poses a risk of recurrence, and the efficacy of existing treatments is limited. Consequently, there is an urgent need to identify new prognostic markers and potential therapeutic targets. N6-methyladenosine (m6A) mRNA methylation is involved in tumorigenesis and progression, yet the role of m6A RNA methylation regulators in PTC remains unclear. The Cancer Genome Atlas database was utilized to analyze 17 m6A regulators in PTC. Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) was markedly down-regulated in PTC, yet higher IGF2BP1 expression predicts better 5-year survival, acting as an independent prognostic marker with high accuracy. Elevated IGF2BP1 also indicated greater sensitivity to doxorubicin and sunitinib. Clinically, low IGF2BP1 correlated with central lymph-node metastasis and BRAFV600E mutation. Additionally, IGF2BP1 overexpression suppresses thyroid carcinoma cell proliferation, invasion, and migration. In conclusion, High expression of IGF2BP1 was associated with a favorable prognosis in PTC, and it served as an independent prognostic factor and a potential therapeutic target for PTC.

Indexed as

AdenosineRNA-Binding ProteinsThyroid Cancer, PapillaryThyroid NeoplasmsBiomarkers, TumorCell Line, TumorCell MovementCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansPrognosisRNA MethylationAdenosineBiomarkers, TumorIGF2BP1 protein, humanN-methyladenosineRNA-Binding ProteinsIGF2BP1N6-methyladenosinePapillary thyroid carcinomaPredictive factor

Identifiers

PMID41807576
PMCPMC12979607

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.